194 related articles for article (PubMed ID: 33111626)
1. Commonly Reported Adverse Events Associated With Pediatric Immunotherapy: A Systematic Review From the Children's Oncology Group.
Withycombe JS; Carlson A; Coleman C; Leslie SL; Skeens M; Tseitlin H; Duffy EA
J Pediatr Oncol Nurs; 2021; 38(1):16-25. PubMed ID: 33111626
[TBL] [Abstract][Full Text] [Related]
2. Evidence-Based Recommendations for Education Provided to Patients and Families Regarding the Adverse Events of ALK and MEK Inhibitors: A Systematic Review From the Children's Oncology Group.
Fisher B; Meyer A; Brown A; Conway Keller M; McKeown T; Tiller J; Saylor KM; Duffy EA
J Pediatr Hematol Oncol Nurs; 2024; 41(2):114-128. PubMed ID: 38549368
[No Abstract] [Full Text] [Related]
3. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
4. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials.
Unger JM; Vaidya R; Albain KS; LeBlanc M; Minasian LM; Gotay CC; Henry NL; Fisch MJ; Lee SM; Blanke CD; Hershman DL
J Clin Oncol; 2022 May; 40(13):1474-1486. PubMed ID: 35119908
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
[TBL] [Abstract][Full Text] [Related]
6. Student and educator experiences of maternal-child simulation-based learning: a systematic review of qualitative evidence protocol.
MacKinnon K; Marcellus L; Rivers J; Gordon C; Ryan M; Butcher D
JBI Database System Rev Implement Rep; 2015 Jan; 13(1):14-26. PubMed ID: 26447004
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.
Bossi P; Botta L; Bironzo P; Sonetto C; Musettini G; Sbrana A; Di Giannantonio V; Locati LD; Di Maio M; Antonuzzo A
Future Oncol; 2019 Jul; 15(21):2543-2553. PubMed ID: 31240949
[No Abstract] [Full Text] [Related]
8. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
[TBL] [Abstract][Full Text] [Related]
9. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Maillet D; Gan HK; Blay JY; You B; Péron J
Eur J Cancer; 2016 Jan; 52():26-32. PubMed ID: 26630531
[TBL] [Abstract][Full Text] [Related]
10. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
11. Child and adolescent self-report symptom measurement in pediatric oncology research: a systematic literature review.
Pinheiro LC; McFatrich M; Lucas N; Walker JS; Withycombe JS; Hinds PS; Sung L; Tomlinson D; Freyer DR; Mack JW; Baker JN; Reeve BB
Qual Life Res; 2018 Feb; 27(2):291-319. PubMed ID: 28879501
[TBL] [Abstract][Full Text] [Related]
12. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Pediatric Oncology: An Overview of Therapy Types and Nursing Implications.
Warren CB
Clin J Oncol Nurs; 2018 Dec; 22(6):649-655. PubMed ID: 30452014
[TBL] [Abstract][Full Text] [Related]
14. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
15. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
16. Using a cancer registry to capture signals of adverse events following immune and targeted therapy for melanoma.
Aguiar JP; Cardoso Borges F; Murteira R; Ramos C; Gouveia E; Passos MJ; Miranda A; da Costa FA
Int J Clin Pharm; 2018 Aug; 40(4):852-861. PubMed ID: 29860707
[TBL] [Abstract][Full Text] [Related]
17. The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.
Reeve BB; Withycombe JS; Baker JN; Hooke MC; Lyons JC; Mowbray C; Wang J; Freyer DR; Joffe S; Sung L; Tomlinson D; Gold SH; Hinds PS
Pediatr Blood Cancer; 2013 Jul; 60(7):1231-6. PubMed ID: 23335328
[TBL] [Abstract][Full Text] [Related]
18. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
[TBL] [Abstract][Full Text] [Related]
20. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]